Redx Pharma plc Share Purchase by Directors (3953A)

TIDMREDX

RNS Number : 3953A

Redx Pharma plc

27 December 2017

REDX PHARMA PLC

("Redx" or "the Company")

Share Purchases by Directors

Alderley Park, December 27 2017- Redx Pharma (AIM:REDX), the drug discovery and development company, announces that it has been notified that Iain Ross, Executive Chairman, has on Friday 22 December acquired 102,000 Redx ordinary shares at a price of 20.75 pence per share. Following this, Mr Ross will hold 450,000 ordinary shares in the Company, representing 0.36 per cent. of the issued share capital.

The Company also announces that Non-Executive Director Mr Peter Presland has on Friday 22 December acquired 120,000 Redx ordinary shares at a price of 22 pence per share. Mr Presland purchased the shares through his self-invested personal pension (SIPP). Following this, Mr Presland will hold 120,000 ordinary shares in the Company, representing 0.09 per cent of the issued share capital.

The Company also announces that Non-Executive Director Dr Bernhard Kirschbaum has today acquired 50,000 Redx ordinary shares at a price of 21 pence per share. Following this, Dr Kirschbaum will hold 50,000 ordinary shares in the Company, representing 0.04 per cent of the issued share capital.

For further information, please contact:

 
Redx Pharma Plc                      T: +44 1625 
                                      469 918 
Iain Ross, Executive Chairman 
 
Cantor Fitzgerald Europe (Nominated   T: +44 20 
 Advisor & Broker)                     7894 7000 
Phil Davies 
 
WG Partners LLP (Joint Broker)       T: +44 20 
                                      3705 9330 
Claes Spång/ Chris Lee/ David 
 Wilson 
 
FTI Consulting                       T: +44 20 
                                      3727 1000 
Simon Conway/Stephanie Cuthbert 
 

About Redx Pharma

Redx Pharma discovers and develops proprietary, small molecule drugs to address areas of high unmet medical need in cancer and fibrosis. In cancer, Redx pursues targeted therapies where a biomarker can potentially be used for selecting those patients that are most likely to benefit from therapy, and/or drugs that are designed to disrupt cancer resistance pathways. In fibrosis, the Company is focused on developing treatments that will stop and reverse the formation of fibrotic tissue. In both therapeutic areas Redx's aim is to develop drugs whose profile suggests they will be best in class, if not first in class.

 
 Notification of a Transaction pursuant to Article 
  19(1) of Regulation (EU) No. 596/2014 
--------------------------------------------------------- 
 1    Details of the person discharging managerial 
       responsibilities/person closely associated 
---  ---------------------------------------------------- 
 a.   Name                     Iain Ross 
                              --------------------------- 
 2    Reason for 
       notification 
---  -----------------------  --------------------------- 
 a.   Position/Status          Executive Chairman 
---  -----------------------  --------------------------- 
 b.   Initial notification/    Initial Notification 
       Amendment 
---  -----------------------  --------------------------- 
 3    Details of the issuer, emission allowance 
       market participant, auction platform, auctioneer 
       or auction monitor 
     ---------------------------------------------------- 
 a.   Name                     Redx Pharma Plc 
---  -----------------------  --------------------------- 
 b.   LEI                      213800HMS4EBXO589Y37 
---  -----------------------  --------------------------- 
 4    Details of the transaction(s): section to 
       be repeated for (i) each type of instrument; 
       (ii) each type of transaction; (iii) each 
       date; and (iv) each place where transactions 
       have been conducted 
---  ---------------------------------------------------- 
 a.   Description              Ordinary Shares of 1p each 
       of the financial 
       instrument, 
       type of instrument 
                                ISIN: GB00BSNB6S51 
       Identification 
       Code 
---  -----------------------  --------------------------- 
 b.   Nature of the            Purchase 
       transaction 
---  -----------------------  --------------------------- 
 c.   Price(s) and             102,000 
       volume(s) 
                                20.75 pence 
---  -----------------------  --------------------------- 
 d.   Aggregated               N/A - Single Transaction 
       information 
       - Aggregated 
       Volume 
       - Price 
---  -----------------------  --------------------------- 
 e.   Date of the              22/12/17 
       transaction 
---  -----------------------  --------------------------- 
 f.   Place of the             Outside of trading venue 
       transaction 
---  -----------------------  --------------------------- 
 
 
 Notification of a Transaction pursuant to Article 
  19(1) of Regulation (EU) No. 596/2014 
--------------------------------------------------------- 
 1    Details of the person discharging managerial 
       responsibilities/person closely associated 
---  ---------------------------------------------------- 
 a.   Name                     Peter Presland 
                              --------------------------- 
 2    Reason for 
       notification 
---  -----------------------  --------------------------- 
 a.   Position/Status          Non-executive Director 
---  -----------------------  --------------------------- 
 b.   Initial notification/    Initial Notification 
       Amendment 
---  -----------------------  --------------------------- 
 3    Details of the issuer, emission allowance 
       market participant, auction platform, auctioneer 
       or auction monitor 
     ---------------------------------------------------- 
 a.   Name                     Redx Pharma Plc 
---  -----------------------  --------------------------- 
 b.   LEI                      213800HMS4EBXO589Y37 
---  -----------------------  --------------------------- 
 4    Details of the transaction(s): section to 
       be repeated for (i) each type of instrument; 
       (ii) each type of transaction; (iii) each 
       date; and (iv) each place where transactions 
       have been conducted 
---  ---------------------------------------------------- 
 a.   Description              Ordinary Shares of 1p each 
       of the financial 
       instrument, 
       type of instrument 
                                ISIN: GB00BSNB6S51 
       Identification 
       Code 
---  -----------------------  --------------------------- 
 b.   Nature of the            Purchase 
       transaction 
---  -----------------------  --------------------------- 
 c.   Price(s) and             120,000 
       volume(s) 
                                22 pence 
---  -----------------------  --------------------------- 
 d.   Aggregated               N/A - Single Transaction 
       information 
       - Aggregated 
       Volume 
       - Price 
---  -----------------------  --------------------------- 
 e.   Date of the              22/12/17 
       transaction 
---  -----------------------  --------------------------- 
 f.   Place of the             Outside of trading venue 
       transaction 
---  -----------------------  --------------------------- 
 
 
 Notification of a Transaction pursuant to Article 
  19(1) of Regulation (EU) No. 596/2014 
--------------------------------------------------------- 
 1    Details of the person discharging managerial 
       responsibilities/person closely associated 
---  ---------------------------------------------------- 
 a.   Name                     Bernhard Kirschbaum 
                              --------------------------- 
 2    Reason for 
       notification 
---  -----------------------  --------------------------- 
 a.   Position/Status          Non-executive Director 
---  -----------------------  --------------------------- 
 b.   Initial notification/    Initial Notification 
       Amendment 
---  -----------------------  --------------------------- 
 3    Details of the issuer, emission allowance 
       market participant, auction platform, auctioneer 
       or auction monitor 
     ---------------------------------------------------- 
 a.   Name                     Redx Pharma Plc 
---  -----------------------  --------------------------- 
 b.   LEI                      213800HMS4EBXO589Y37 
---  -----------------------  --------------------------- 
 4    Details of the transaction(s): section to 
       be repeated for (i) each type of instrument; 
       (ii) each type of transaction; (iii) each 
       date; and (iv) each place where transactions 
       have been conducted 
---  ---------------------------------------------------- 
 a.   Description              Ordinary Shares of 1p each 
       of the financial 
       instrument, 
       type of instrument 
                                ISIN: GB00BSNB6S51 
       Identification 
       Code 
---  -----------------------  --------------------------- 
 b.   Nature of the            Purchase 
       transaction 
---  -----------------------  --------------------------- 
 c.   Price(s) and             50,000 
       volume(s) 
                                21 pence 
---  -----------------------  --------------------------- 
 d.   Aggregated               N/A - Single Transaction 
       information 
       - Aggregated 
       Volume 
       - Price 
---  -----------------------  --------------------------- 
 e.   Date of the              27/12/17 
       transaction 
---  -----------------------  --------------------------- 
 f.   Place of the             Outside of trading venue 
       transaction 
---  -----------------------  --------------------------- 
 

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHOKODQOBDDNBB

(END) Dow Jones Newswires

December 27, 2017 12:45 ET (17:45 GMT)